Loading RPG Life Sciences…
| ₹ Cr | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 196 | 177 | 180 | 169 | 143 |
| Operating profit | 37 | 27 | 34 | 30 | 20 |
| Operating margin | 19.1% | 15.3% | 19.1% | 18.0% | 14.1% |
| Net profit | 31 | 30 | 22 | 26 | 117 |
| Net margin | 15.7% | 16.9% | 12.3% | 15.6% | 82.0% |
| EPS (₹) | 18.60 | 18.08 | 13.38 | 15.90 | 70.96 |
Quarters are labelled by period end.
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 702 | 648 | 577 | 509 |
| Operating profit | 127 | 140 | 112 | 89 |
| Operating margin | 18.0% | 21.7% | 19.4% | 17.5% |
| Net profit | 115 | 183 | 88 | 68 |
| Net margin | 16.4% | 28.3% | 15.2% | 13.3% |
| EPS (₹) | 69.64 | 110.80 | 53.01 | 40.90 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total assets | 793 | 658 | 513 | 419 | — |
| Total liabilities | 188 | 127 | 138 | 112 | — |
| Shareholders’ equity | 605 | 531 | 375 | 308 | — |
| Total debt | 20 | — | 0 | 0 | 1 |
| Cash & equivalents | 150 | 29 | 20 | 25 | — |
| Debt / equity | 0.03 | — | 0.00 | 0.00 | — |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating cash flow | 57 | 78 | 94 | 91 |
| Capital expenditure | -65 | -36 | -69 | -33 |
| Free cash flow | -9 | 42 | 25 | 58 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Return on equity | 19.0% | 34.5% | 23.4% | 22.0% |
| Return on assets | 14.5% | 27.9% | 17.1% | 16.1% |
| Net margin | 16.4% | 28.3% | 15.2% | 13.3% |
Source: Yahoo Finance. Figures in ₹ crore unless stated.
No analyst data available for RPGLIFE. Finnhub coverage is limited for some India-listed stocks.